BPWA
VRTX icon

Beacon Pointe Wealth Advisors’s Vertex Pharmaceuticals VRTX Stock Holding History

Beacon Pointe Wealth Advisors’s Portfolio VRTX Stock Details VRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q4 		$300K Hold
1,367
– – 0.06% 217
2019
Q3 		$231K Sell
1,367
-2
-0.1% -$354 0.05% 233
2019
Q2 		$251K Buy
1,369
+2
+0.1% +$350 0.05% 231
2019
Q1 		$251K Buy
+1,367
New +$252K 0.06% 228

Other funds holding VRTX

T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Beacon Pointe Wealth Advisors's VRTX Position: Q4 2019 in Review

Beacon Pointe Wealth Advisors held its Vertex Pharmaceuticals (VRTX) position steady in Q4 2019 at 1,367 shares worth $300K. The position accounts for 0.06% of the portfolio, ranked #217.

Beacon Pointe Wealth Advisors first reported a position in VRTX in Q1 2019 and has held it in 4 quarters since. 813 funds tracked by Wall St. Rank hold VRTX as of Q4 2019.

  • Beacon Pointe Wealth Advisors held 1,367 shares of Vertex Pharmaceuticals worth $300K as of Q4 2019.
  • Beacon Pointe Wealth Advisors left its Vertex Pharmaceuticals share count unchanged in Q4 2019.
  • Vertex Pharmaceuticals made up 0.06% of Beacon Pointe Wealth Advisors's portfolio in Q4 2019, its #217 holding.
  • Beacon Pointe Wealth Advisors first reported a position in Vertex Pharmaceuticals in Q1 2019 and has held it in 4 quarters since.
  • 813 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q4 2019.

Based on Beacon Pointe Wealth Advisors's 13F filing for Q4 2019, filed 14 Feb 2020.